{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:18:18Z","timestamp":1784827098994,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070033"],"award-info":[{"award-number":["82070033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eosinophil\u2010induced adverse events (Eo\u2010irAEs) have been observed in patients treated with programmed cell death 1\/ligand 1 (PD\u20101\/PD\u2010L1) inhibitors. Surprisingly, the clinical features and outcomes of Eo\u2010irAEs induced by PD\u20101\/PD\u2010L1 inhibitors have not yet been elucidated. This study investigated the characteristics of and risk factors for Eo\u2010irAEs induced by PD\u20101\/PD\u2010L1 inhibitors. We extracted data on Eo\u2010irAEs related to PD\u20101\/PD\u2010L1 inhibitors from the FDA Adverse Event Reporting System (FAERS) from 2015 to 2023. Disproportionality and Bayesian analyses were applied for data mining and analysis. A total of 430 Eo\u2010irAEs induced by PD\u20101\/PD\u2010L1 inhibitors were included in this study. Older male patients were found to be at a high risk of developing Eo\u2010irAEs. Cemiplimab (ROR 2.66 [1.38, 5.13]), nivolumab (ROR 1.82 [1.61, 2.05]), and pembrolizumab (ROR 1.35 [1.13, 1.62]) showed stronger signals than the other drugs. Cemiplimab showed higher signals for Eo\u2010irAEs than other PD\u20101\/PD\u2010L1 inhibitors, with an information component (IC) of 1.41 (IC 0.25:0.73). Patients experienced Eo\u2010irAEs within the first 100\u2009days, with a median onset time of 56 (interquartile range: 17.0\u2013169.0) days. Eo\u2010irAEs were more likely to occur in patients with lung (<jats:italic>n<\/jats:italic>\u2009=\u2009147, 34.83%) and skin tumors (<jats:italic>n<\/jats:italic>\u2009=\u2009145, 34.36%). Eosinophilia (<jats:italic>n<\/jats:italic>\u2009=\u2009193, 44.88%), drug reactions with eosinophilia and systemic symptoms (DRESS) (<jats:italic>n<\/jats:italic>\u2009=\u200998, 22.79%), and eosinophilic fasciitis (<jats:italic>n<\/jats:italic>\u2009=\u200969, 16.05%) were the most common adverse events. Eo\u2010irAEs that were life\u2010threatening or resulted in death comprised 5.15% (<jats:italic>n<\/jats:italic>\u2009=\u200921) and 5.39% (<jats:italic>n<\/jats:italic>\u2009=\u200922) of the patients. PD\u20101\/PD\u2010L1 inhibitors used across a broad spectrum of cancers are associated with an increased risk of Eo\u2010irAEs, which tend to occur early. Although these complications are rare, clinicians using PD\u20101\/PD\u2010L1 inhibitors should be aware of and monitor these potentially serious adverse events related to Eo\u2010irAEs.<\/jats:p>","DOI":"10.1002\/ijc.35398","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:36:01Z","timestamp":1741750561000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eosinophil\u2010induced adverse events induced by treatment with programmed cell death 1\/ligand 1 inhibitors: A comprehensive disproportionality analysis of the <scp>FDA<\/scp> adverse event reporting system"],"prefix":"10.1002","volume":"157","author":[{"given":"Lu","family":"Lyu","sequence":"first","affiliation":[{"name":"Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-5874","authenticated-orcid":false,"given":"Kai","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences  Beijing China"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College  Beijing China"},{"name":"School of Pharmacy Faculty of Medicine, Macau University of Science and Technology  Macau China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01725-x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01291-2"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000372"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00943-z"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.11.014"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2398309"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6724"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138\u201020220403\u201000245"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001075"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13848"},{"issue":"5","key":"e_1_2_10_14_1","article-title":"Atypical presentation of drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient on pembrolizumab: a case report","volume":"16","author":"Tran H","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"e_1_2_10_15_1","article-title":"Moderate\u2010to\u2010severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion Q","year":"2020","journal-title":"Onco Targets Ther"},{"key":"e_1_2_10_16_1","unstructured":"United States Food and Drug Administration.https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15151"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt027"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.932888"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1078560"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2023.07.001"},{"key":"e_1_2_10_22_1","article-title":"Acute eosinophilic pneumonia induced by immune checkpoint inhibitor and anti\u2010TIGIT therapy","volume":"25","author":"Mohammed A","year":"2024","journal-title":"Am J Case Rep"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000001166"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5570"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001252"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15030"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1037"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13109"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33765"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1187937"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002879"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:08:05Z","timestamp":1747303685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,15]]}},"alternative-id":["10.1002\/ijc.35398"],"URL":"https:\/\/doi.org\/10.1002\/ijc.35398","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"2024-10-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}